Searched for
GAEKWAD BID FOR RELIGARE
Gaekwad bid for Religare refused, 'lacks fin proof'Gaekwad had requested Sebi's exemption under takeover rules to propose ₹275 a share for Religare, offering a 17% premium to the Burmans' of...- Saluja no longer Director on Religare Enterprises boardThe board has appointed Praveen Kumar Tripathi, a non-executive independent director, as chairperson until June 30, 2025, said a separate e...
- Rashmi Saluja ceases to be director of Religare as shareholders shoot down her re-appointmentReligare Enterprises on Thursday said its executive chairperson Rashmi Saluja ceased to be Director on its board as she did not get approva...
- Religare's Rashmi Saluja accused of tampering with REL AGM agendaAt Religare Enterprises' AGM, executive chairperson Rashmi Saluja removed the agenda item regarding her retirement and reappointment, despi...
- Gaekwad submits fresh plea on competing offer to that of Burmans for ReligareSebi had earlier returned Gaekwad's application, citing non-compliance with its regulations. Gaekwad said he is ready to establish an escro...
- US investor Danny Gaekwad Developments & Investments seeks Sebi exemption for Religare takeoverDanny Gaekwad Developments & Investments has requested Sebi to allow a public announcement for competing offer against Burmans' open offer ...
- Delhi HC refuses to stay Burman family’s open offer to buy an additional 26% stake in ReligareThe Delhi High Court has refused to stay the Burman family’s open offer to acquire an additional 26% stake in Religare Enterprises. The cou...
- Dr Agarwal's Healthcare IPO opens for subscription as GMP remains muted. Should you subscribe?Dr Agarwal's Healthcare IPO is now open for subscription, with a price range of Rs 382-402 per share. Despite a significant OFS component a...
- Malpani Pipes And Fittings IPO: Check key dates, price band, GMP and other detailsMalpani Pipes And Fittings IPO opened for subscription, aiming to raise around Rs 26 crore. The IPO price band is fixed at Rs 85-90 apiece,...
Load More
